Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness

Nature Medicine

Volumn 10, Issue 10, 2004, Pages 1117-1121

  Cohen, Ted ^a   Murray, Megan ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; DISEASE TRANSMISSION; EPIDEMIC; EPIDEMIOLOGICAL DATA; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; HOMOZYGOTE; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; TUBERCULOSIS CONTROL;

DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; SPECIES SPECIFICITY; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

ACTINOBACTERIA (CLASS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 7044285767     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1110     Document Type: Article

References (30)

1. Blower, S.M. & Gerberding, J.L. Understanding, predicting and controlling the emergence of drug- resistant tuberculosis: a theoretical framework. J. Mol. Med. 76, 624-636 (1998).
2. Dye, C. & Williams, B.G. Criteria for the control of drug-resistant tuberculosis. Proc. Natl. Acad. Sci. USA 97, 8180-8185 (2000).
3. Dye, C. & Espinal, M.A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B. Biol. Sci. 268, 45-52 (2001).
4. World Health Organization. Anti-tuberculosis drug resistance in the world, report #3 (WHO, Geneva, 2004).
5. Andersson, D.I. & Levin, B.R. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2, 489-493 (1999).
6. Anderson, R.M. & May, R.M. Infectious Diseases of Humans: Dynamics and Control. (Oxford University Press, Oxford, 1991).
7. Grenfell, B.T. & Anderson, R.M. Pertussis in England and Wales: an investigation of transmission dynamics and control by mass vaccination. Proc. R. Soc. Lond. B Biol. Sci. 22, 213-252 (1989).
8. Blower, S.M., Small, P.M. & Hopewell, P.C. Control strategies for tuberculosis epidemics: new models for old problems. Science 273, 497-500 (1996).
9. Blower, S.M. et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1, 815-821 (1995).
10. Vynnycky, E. & Fine, P.E. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119, 183-201 (1997).
11. Dye, C., Garnett, G.P., Sleeman, K. & Williams B.G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy: Directly observed short-course therapy. Lancet 352, 1886-1891 (1998).
12. Castillo-Chavez, C. & Feng, Z. To treat or not to treat: the case of tuberculosis. J. Math. Biol. 35, 629-656 (1997).
13. Schrag, S.J., Perrot, V. & Levin, B.R. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. R. Soc. Lond. B Biol. Sci. 264, 1287-1291 (1997).
14. Lipsitch, M. & Levin, B.R. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41, 363-373 (1997).
15. Ordway, D.J., Sonnenberg, M.G., Donahue, S.A., Belisle, J.T. & Orme, I.M. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect. Immun. 63, 741-743 (1995).
16. Sherman, D.R. et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272, 1641-1643 (1996).
17. Garcia-Garcia, M.L. et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch. Intern. Med. 160, 630-636 (2000).
18. Teixeira, L. et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 5, 321-328 (2001).
19. Cohen, T., Sommers, B. & Murray, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3, 13-21 (2003).
20. Khatri, G.R. & Frieden, T.R. Controlling tuberculosis in India. N. Engl. J. Med. 347, 1420-1425 (2002).
21. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO report (WHO/CDS/TB/97.220, Geneva, 1997).
22. Espinal, M.A. et al. Standard short-course chemotherapy for drug-resistant tuberculosis treatment outcomes in 6 countries. JAMA 283, 2537-2545 (2000).
23. Styblo, K. Epidemiology of Tuberculosis: Selected Papers (Royal Netherlands Tuberculosis Association, The Hague, 1991).
24. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677-686 (1999).
25. Espinal, M.A. et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 344, 1294-1303 (2001).
26. Verver, S. et al. Transmission of tuberculosis in a high incidence urban community in South Africa. Int. J. Epidemiol. 33, 351-357 (2004).
27. Small, P.M. et al. The epidemiology of tuberculosis in San Francisco: A population-based study using conventional and molecular methods. N. Engl. J. Med. 330, 1703-1709 (1994).
28. Murray, C.J. & Salomon, J.A. Modeling the impact of global tuberculosis control strategies. Proc. Natl. Acad. Sci. USA 95, 13881-13886 (1998).
29. Farmer, P. & Kim, J.Y. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". BMJ 317, 671-674 (1998).
30. van Rie, A. et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341, 1174-1179 (1999).